EGLN1 and anemia (phenotype): In situ inhibitor synthesis and screening (ISISS) links high‐throughput bioorthogonal synthesis with screening tor target binding by fluorescence, as exemplified by the efficient identification of in vivo orally active inhibitors of PHD2, a target for anemia treatment.